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Background: Heart failure (HF) is a burden to patients and health care systems. The objectives of HF treatment
are to improve health related quality of life (HRQoL) and reduce mortality and morbidity. We aimed to
evaluate determinants of health-related quality of life (HRQoL) in patients with iron deﬁciency and HF treated
with intravenous (i.v.) iron substitution or placebo.
Methods: A randomised, double-blind, placebo-controlled trial (n = 459) in iron-deﬁcient chronic heart failure
(CHF) patients with or without anaemia studied clinical and HRQoL beneﬁts of i.v. iron substitution using ferric
carboxymaltose (FCM) over a 24-week trial period. Multivariate analysis was carried out with various clinical
variables as independent variables and HRQoL measures as dependent variables.
Results:Mean change from baseline of European Quality of Life— 5 Dimensions (EQ-5D) (value set-based) util-
ities (on a 0 to 100 scale) at week 24 was 8.91 (i.v. iron) and 0.68 (placebo; p b 0.01). In a multivariate analysis
excluding baseline HRQoL, a higher exercise tolerance and i.v. iron substitution positively inﬂuenced HRQoL,
whereas impaired renal function and a history of stroke had a negative effect. The level of HRQoL was also
inﬂuenced by country of residence.WhenbaselineHRQoLwas factored in, themultivariatemodel remained stable.
Conclusion: In this study, i.v. iron substitution, exercise tolerance, stroke, country of residence and renal function
inﬂuenced measures of HRQoL in patients with heart failure and iron deﬁciency.© 2013 The Authors. Published by Elsevier Ireland Ltd. Open access under CC BY license.e reliability and freedom from
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Heart failure (HF) is a leading cause of morbidity and mortality
and poses a signiﬁcant burden to health systems [1]. It contributes
to about 2% of all inpatient bed days and approximately 5% of all
emergency medical admissions to hospitals in the United Kingdom
(UK) [2] and is the primary diagnosis on admission to German hospitals
[3]. The primary objective of HF treatment is to improve health-related
quality of life (HRQoL) and reduce mortality and morbidity [2,4].
Previous multivariate analyses have reported New York Heart
Association (NYHA) class, the 6-min walk test and depression as
predictors of HRQoL in HF patients [5–7].
In the cycle of oxygen uptake, transport and storage, iron plays
an important role [8,9]. It has been shown that intravenous (i.v.) re-
pletion of iron can diminish symptoms and improve HRQoL in
chronic heart failure (CHF) patients [10–12]. Treatment with ferric
carboxymaltose (FCM), an i.v. iron preparation, resulted in improved license.
3879F.S. Gutzwiller et al. / International Journal of Cardiology 168 (2013) 3878–3883HRQoL in FAIR-HF, an international (Table 1), randomised, double-blind,
placebo-controlled trial (n = 459) that enrolled iron-deﬁcient CHF
patients with or without anaemia. Study patients were treated with
i.v. iron substitution or placebo over the 24 week trial period [10].
A recent analysis showed that in the FAIR-HF trial, mean utilities
measured by the European Quality of Life — 5 Dimensions (EQ-5D)
questionnaire [13] were higher in the i.v. iron substitution arm,
resulting in an incremental cost-effectiveness ratio of 3977 pound
sterling (£), which was below the threshold of £20,000–£30,000Table 1
Baseline demographic and clinical characteristics of the FAIR-HF intention-to-treat populat
Variable
Demographics Age — years§§
Female sex§§
Country§§
Argentina
Czech Republic
Germany
Spain
Greece
Italy
Norway
Poland
Romania
Russia
Ukraine
Employment status§§
Unemployed, employed or regularly retir
Early retirement due to CHF
Clinical characteristics Anaemic⁎
NYHA class§§
II
III
LVEF — %
Heart rate — beats per minute§
eGFR — mL/min§§
BMI — kg/m2§§
Aetiology of CHF: ischaemic§§
6-min walk test distance — metres§§
Concomitant medication
Angiotensin receptor blocker§
Angiotensin-converting-enzyme inhibitor
Laboratory measurements
Haemoglobin — g/L†§§
Serum ferritin — μg/L
Transferrin saturation — %
Risk factors/medical History of… Smoking
Non-smoker
Former smoker
Current smoker
Hypertension (treated with drug)§§
Dyslipaemia (treated with drug)§§
Diabetes
Myocardial infarction (MI)
Angina pectoris§ (AP)
MI and AP§
Stroke§§
Transient ischemic attack
Valvular heart disease
Atrial ﬁbrillation
Procedures
Coronary angiography§
Coronary revascularization (CABG, PTCA)
HRQoL at baseline⁎⁎ EQ-5D utility
EQ-5D VAS scores
KCCQ
Data presented are mean value ± SD or number (%) of patients. Values were calculated fro
AP, angina pectoris; BMI, body mass index; CABG, coronary artery bypass graft; CHF, congest
Life — 5 Dimensions; g, gramme; IDA, iron deﬁciency anaemia; KCCQ, Kansas City Cardiomyo
NYHA, New York Heart Association; PTCA, percutaneous transluminal coronary angioplasty
⁎ Deﬁned as Hb b 120 g/L for females and Hb b 130 g/L for males.
† Due to missing values, the n for haemoglobin are 298 (i.v. iron) and 153 (placebo).
§ Determinants chosen as candidate predictors in univariate analysis (p ≤ 0.25).
§§ Determinants chosen as possible determinants for the multivariate analysis (p ≤ 0.05)
⁎⁎ Due tomissing values, the n for EQ-5D utility are 298 (i.v. iron) and 154 (placebo); for EQ-5typically used by the UK National Institute for Health and Clinical
Excellence [14]. Health-state utilities are preference-basedmeasures
of HRQoL with a foundation in economic theory. They are frequently
used in health economic analyses to calculate quality-adjusted life
years (QALYs) [15]. The EQ-5D is a commonly used measure for
this purpose [14].
This multivariate analysis further explores the EQ-5D-based utility
effect observed in the i.v. iron substitution group of the FAIR-HF trial,
by evaluating a wider range of determinants of HRQoL. The aims areion, according to study group.
Ferric carboxymaltose (n = 304) Placebo (n = 155)
67.8 ± 10.3 67.4 ± 11.1
159 (52.3) 85 (54.8)
5 (1.6) 1 (0.6)
13 (4.3) 4 (2.6)
8 (2.6) 3 (2.0)
14 (4.6) 8 (5.2)
6 (2.0) 5 (3.2)
7 (2.3) 4 (2.6)
0 (–) 2 (1.3)
43 (14.1) 17 (11.0)
10 (3.3) 6 (3.9)
133 (43.7) 67 (43.2)
65 (21.4) 38 (24.5)
ed 254 (83.6) 133 (86.0)
50 (16.4) 22 (14.2)
181 (59.5) 82 (53.0)
53 (17.4) 29 (18.7)
251 (82.6) 126 (81.3)
31.9 ± 5.5 33.0 ± 6.1
70.9 ± 11.4 71.9 ± 11.7
63.7 ± 21.2 64.8 ± 25.3
27.9 ± 4.7 28.1 ± 5.1
245 (80.6) 123 (79.4)
274 ± 105 269 ± 109
33 (10.9) 22 (14.2)
227 (74.7) 104 (67.1)
119 ± 12.6 119.5 ± 13.8
52.5 ± 54.5 60.1 ± 66.5
17.7 ± 12.6 16.7 ± 8.4
225 (74.0) 114 (73.6)
56 (18.4) 27 (17.4)
23 (7.6) 14 (9.0)
243 (79.9) 128 (82.6)
144 (47.4) 70 (45.2)
93 (30.6) 37 (23.9)
168 (55.3) 90 (58.1)
171 (56.3) 89 (57.4)
95 (31.2) 57 (36.8)
24 (7.9) 9 (5.9)
9 (3.0) 6 (3.9)
85 (28.0) 48 (31.0)
94 (30.9) 44 (28.4)
85 (28.0) 39 (25.2)
64 (21.0) 31 (20.0)
57.7 ± 18.8 57.7 ± 17.9
54.3 ± 17.1 54.1 ± 15.2
52.8 ± 19.5 52.4 ± 17.3
m the study data by the authors. In FAIR-HF a 2:1 randomisation was used [10].
ive heart failure; eGFR, estimated glomerular ﬁltration rate; EQ-5D, European Quality of
pathy Questionnaire; LVEF, left ventricular ejection fraction; MI, myocardial infarction;
; μg, micrograms.
.
D VAS scores 295 (i.v. iron) and 152 (placebo); for KCCQ 286 (i.v. iron) and 145 (placebo).
3880 F.S. Gutzwiller et al. / International Journal of Cardiology 168 (2013) 3878–3883to gain a better understanding of determinants of utility and HRQoL
in CHF patients and to validate predictors of HRQoL previously iden-
tiﬁed from the FAIR-HF dataset in univariate analyses [16].
2. Methods
This is a retrospective within-trial analysis of the FAIR-HF intention-to-treat (ITT)
population including 459 patients with NYHA functional classes II and III, impaired left
ventricular ejection fraction, and iron deﬁciency. Patients were randomly assigned to
receive either i.v. iron substitution with FCM or placebo. During a correction phase,
patients received weekly injections until iron repletion was achieved. A subsequent
maintenance phase with 4-weekly injections followed. Further details were previously
described [10,17]. Table 1 shows baseline demographic and clinical characteristics of
the study population.
All analyses were performed at the patient level following an a-priori speciﬁed
analysis plan. Available data for independent variables were the data from FAIR-HF
baseline assessments. Data for dependent variables were from the FAIR-HF assessments
at week 24 (end of trial). HRQoL measures from FAIR-HF used for this analysis include
EQ-5D-based utilities and the Kansas City Cardiomyopathy Questionnaire (KCCQ) [18]
measurements at baseline and week 24. The main endpoint was EQ-5D-based utility
measured at week 24. The secondary endpoint consisted of HRQoL represented by
KCCQ summary score at week 24. In the case of missing values of single questionnaire
items, the last recorded observation was imputed using the ‘last observation carried
forward’ (LOCF)method. Patients withmissing baseline information for a given endpoint,
and patients with only baseline information, were excluded from the respective analyses.
The EQ-5D is an instrument designed for self-completion by respondents. It
comprises two parts: First, respondents report their health status according to a
ﬁve-dimensional classiﬁcation including mobility, self-care, usual activities, pain/
discomfort and anxiety/depression. Each dimension is represented by a three
level ordered category item, which leads to a total of 243 possible health ratings.
In the current analysis, these ratings were valued using the standard European
time trade-off value set to achieve utility estimates [19]. Second, the respondents
record their self-perceived health status using a graduated visual analogue scale
(VAS), with grades from 0 meaning “death” to 100 meaning “perfect health”. The
EQ-5D is a generic, i.e. non-disease-speciﬁc HRQoL instrument which has been
validated and shown to be sensitive, internally consistent, and reliable in the general
population and different patient groups [20–22]. The KCCQ is a self-administered, disease-
speciﬁc 23-item questionnaire for measuring HRQoL in patients with CHF. It quantiﬁes
physical function, symptoms (frequency, severity and recent change), social function,
self-efﬁcacy and knowledge, and HRQoL [18].
3. Approach to covariate selection
Available baseline variables from the FAIR-HF trial data were
selected as candidate predictors (independent variables) if a potential
inﬂuence on HRQoL could be assumed, i.e. if an association (e.g. clinical
or biological) with the response variables (dependent variables, HRQoL
outcomes) was expected on biological or clinical grounds. Factors
selected as candidate predictors of HRQoL were demographic factors
such as country of residence, age and gender; clinical factors, such as
NYHA class at baseline, exercise tolerance (6-min walk test), estimated
glomerular ﬁltration rate (eGFR) and depression (approximated by the
EQ-5D anxiety/depression item), and medical history items, such as
history of stroke, hypertension, angina pectoris, ischaemic heart disease
and treatment regimen (for a complete list of candidate predictors
please refer to Table 1).
4. Statistical analysis
Endpoints and covariates were described (Table 1); continuous
and discrete numerical variables based on the mean with standard
deviation (SD), median and range. Non-plausible, outlying values were
excluded from analysis. For binary and categorical variables, frequencies
and percentages were used. All analyses were performed using
Stata/MP 11 or Stata/SE 12 (StataCorp LP, College Station, TX, USA).
4.1. Selection of candidate predictors for multivariate analysis
(univariate analysis)
Univariate analyses were performed depending on the underlying
distribution of the involved variables. Based on graphical inspection,
it was assumed that variables with small deviations from the normaldistribution would not distort any results, thus they were treated as
normally distributed. Associations of candidate predictors and the
continuous endpoints were determined. For continuous predictors,
Pearson (for linear association, assumption of normality) or Spearman
rank (for monotone association, non-normality) correlations were
performed to measure the strength of the association. Scatter plots
were used to describe associations graphically (data on ﬁle). Given
approximate normality of the endpoint variables, unpaired t-tests or
ANOVA were performed to assess associations with binary or cate-
gorical predictors, respectively. All statistical tests were carried out
two-sided at a 5% signiﬁcance level, and 95% conﬁdence intervals
(CIs) were obtained, if applicable. Candidate predictors were further
assessed in multivariate analysis if a trend was seen in univariate
analysis (p ≤ 0.25).5. Multivariate analysis
Normality of endpoint variables was assessed graphically using
histograms. In the absence of relevant skewness, multivariate linear
regression was used to assess the joint explanatory value of the
candidate predictors. The analysis was carried out with and without
HRQoL (EQ-5D utility or KCCQ score) at baseline. The rationale behind
this approach is that an analysis without baseline HRQoL is more
suitable for showing the inﬂuence of pre-existing factors (that might
otherwise be absorbed into the effect of baseline HRQoL), whereas an
analysis with baseline HRQoL better shows effects occurring after
baseline and during the trial period.
The selection process of potential predictors for the multivariate
analysis was performed using both stepwise backward selection and
stepwise forward selection procedures, results were compared for
consistency. Decision criterion for variable selection into the ﬁnal
model was p ≤ 0.05. Interactions and collinearities between explana-
tory variables were assessed. To avoid over-modelling, signiﬁcant
interaction terms were to be included in ﬁnal models only if they
inﬂuenced the main effects substantially. Model ﬁt was assessed
using normal quantile plots of residuals and plots of residuals against
explanatory variables and ﬁtted values. The predictive ability of the
ﬁnal models and the explanatory value of the individual covariates
were monitored using the adjusted R-squared statistic that shows
the fraction of variance of the dependent variable that is explained
by the model.
For comparison, alternative multivariate regression models were
also estimated using (a) EQ-5D VAS scores (instead of EQ-5D
questionnaire-based utilities) at baseline as a predictor variable
and (b) the log of the main endpoint variable (due to a slightly
skewed distribution of the endpoint variable) and (c) the KCCQ
score at week 24 as the endpoint (with and without baseline
HRQoL). In the model with KCCQ as endpoint and baseline
HRQoL, the EQ-5D anxiety/depression item (baseline value) was
tested as an additional possible predictor. Because Russian and
Ukrainian patients accounted for a large part of the patient popu-
lation, the regression additionally was performed using a variable
distinguishing Russian and Ukrainian patients from all others,
instead of the variable representing individual countries that
was otherwise used.6. Results
6.1. Characteristics of the study patients
Relevant clinical characteristics of the FAIR-HF ITT population of
n = 459 patients are presented in Table 1 (for a consort diagram
see Anker et al. [10]). Patients were enrolled from June 2007, through
December 2008, in 75 sites in 11 countries [10].
Fig. 1. Boxplot showing median, range, interquartile range and outliers of the mean EQ-5D utility and KCCQ values at baseline and week 24.
3881F.S. Gutzwiller et al. / International Journal of Cardiology 168 (2013) 3878–38836.2. Description of endpoints
In the analyses involving EQ-5D utilities, 7 observations with
missing values at baseline were excluded from analysis. In the anal-
yses additionally including EQ-5D VAS scores, 12 observations with
missing values were excluded. In the case of the KCCQ summary
score, exclusions amounted to 11 observations with missing values
at baseline and 17 with values only for baseline. Both endpoints,
EQ-5D utility and KCCQ summary score, indicated better HRQoL at
week 24 than at baseline; the improvement was signiﬁcantly higher
in the i.v. iron substitution arm (Fig. 1). Change from baseline for
EQ-5D utility was 8.9 (i.v. iron; SD ± 22.43; 15%) and 0.7 (placebo;
SD ± 21.15; 1%), respectively. For KCCQ summary scores change
from baseline was 12.8 (i.v. iron; SD ± 21.22; 24%) and 6.2 (placebo;
SD ± 18.46; 12%), respectively (Fig. 1).
6.3. Predictors of EQ-5D utility
A total of 20 candidate predictors showed a possible relationship
with the main endpoint variable (p b 0.25) in univariate analysis
and were subsequently included in the multivariate analysis as possi-
ble determinants. The BMI variable only had p b 0.25 due to two out-
lying values (with BMI values of 48 and 49 kg/m2). BMI was thus not
included in the multivariate analysis.
Multivariate analysis without baseline HRQoL, which reﬂects in-
ﬂuences of pre-existing factors well, showed i.v. iron substitution,
lower NYHA class and a better result in the 6-min walk test to be
associated with higher HRQoL; history of stroke and reduced renal
function were associated with lower HRQoL (Table 2). There was
also an effect of country of residence on HRQoL. Apart from country,
i.v. iron substitution showed the strongest impact on the adjusted
R-squared; which for the overall model was 0.17.
In the multivariate model including baseline HRQoL, which fo-
cuses on the inﬂuence of effects occurring after baseline, the effects
of 6-min walk test and NYHA class became non-signiﬁcant. Othereffects remained stable. (Table 2). This model had an adjusted
R-squared of 0.32.
When instead of single countries, Russian and Ukrainian patients
were compared to the patients from all other countries, the effects
of the other predictor variables remained stable (with and without
baseline HRQoL). When the log of EQ-5D questionnaire-based utility
or EQ-5D VAS scores was used as alternative endpoints, the effects
of all predictor variables remained stable. This was also true when
analysed without LOCF performed at EQ-5D item level.
6.4. Predictors of KCCQ-based HRQoL
The effects observed in the models of EQ-5D questionnaire-based
utility remained stable when KCCQ summary scores from week 24
were used as the endpoint (Table 3).
When baseline KCCQ values were included, history of hypertension
was observed as an additional determinant (p = 0.03, coefﬁcient 4.83)
and the 6-minwalk test and NYHA class became non-signiﬁcant.When,
in addition to the baseline KCCQ values, the EQ-5D anxiety/depression
item (baseline value) was included as a potential predictor, it was
not signiﬁcant.
Signiﬁcant interactions for the model with KCCQ baseline were
found between i.v. iron substitution and KCCQ baseline. This interac-
tion did not substantially improve the explanatory value of the model
and was therefore not included in the ﬁnal version.
Analysis of residuals did not indicate any issues with model
speciﬁcations. Collinearities between explanatory variables were
not found to be problematic in their respective context.
7. Discussion
7.1. Principal ﬁndings
One important ﬁnding of the FAIR-HF trial was that i.v. iron sub-
stitution can improve HRQoL in iron deﬁcient CHF patients [10,16].
Table 2
Main effects model of EQ-5D at time point 24 weeks with and without baseline HRQoL (EQ-5D).
Coefﬁcient 95% CI p Coefﬁcient 95% CI p
Predictor Model without baseline HRQoL (n = 459) Model with baseline HRQoL (n = 452)
i.v. iron 7.98 3.80; 12.15 b0.01 8.12 4.38; 11.86 b0.01
NYHA class 6.34 0.51; 12.18 0.03 – – –
eGFR† 0.15 0.05; 0.24 b0.01 0.20 0.11; 0.23 b0.01
Stroke −9.03 −16.71; −1.35 0.02 −8.62 −15.52; −1.71 0.02
6-min walk test 0.03 0.01; 0.05 0.02 – – –
EQ-5D utility baseline⁎ – – – 0.57 0.47; 0.66 b0.01
Poland Reference Reference
Argentina −0.09 −19.49; 19.32 0.99 4.01 −13.40; 21.42 0.65
Czech Republic −9.76 −21.36; 1.84 0.09 −6.87 −17.20; 3.45 0.19
Germany −20.83 −34.80; −6.87 b0.01 −19.77 −32.13; −7.40 b0.01
Spain −7.00 −17.98; 3.98 0.21 −14.13 −24.05; −4.21 b0.01
Greece −27.23 −42.25; −13.20 b0.01 −20.97 −33.25; −8.69 b0.01
Italy −27.93 −41.90; −13.97 b0.01 −24.33 −36.63; −12.03 b0.01
Norway −0.40 −30.89; 30.09 0.98 3.02 −24.01; 30.04 0.83
Romania −0.53 −12.37; 11.30 0.93 −0.91 −11.48; 9.65 0.86
Russia −18.95 −25.19; −12.71 b0.01 −16.97 −22.49; −11.45 b0.01
Ukraine −19.11 −26.33; −11.88 b0.01 −15.75 −22.01; −9.49 b0.01
Constant 54.63 27.26
All countries combined: p b 0.01.
eGFR, estimated glomerular ﬁltration rate; i.v., intravenous.
⁎ Per increase by 1.
† For a one unit increase in eGFR (mL/min).
3882 F.S. Gutzwiller et al. / International Journal of Cardiology 168 (2013) 3878–3883In this additional within-trial study, we put this result into perspec-
tive by providing a broader analysis of correlates of HRQoL in this pa-
tient group. We found that i.v. iron substitution using FCM, lower
NYHA class and a better result in the 6-min walk test positively
inﬂuenced HRQoL of HF patients, whereas impaired renal function
and a history of stroke negatively affected HRQoL of HF patients.
A further ﬁnding was that patients with a higher HRQoL at baseline
were more likely to maintain or even improve their HRQoL over
time. HRQoL levels differed between countries, which may be attrib-
utable to cultural differences, potential differences among the inves-
tigated collectives. The fact that the models did not change in
relevant aspects when either EQ-5D utility or EQ-5D VAS scores
were used, indicates that the observed intercountry differences
were most probably not due to issues related to either questionnaire
comprehensibility or use of the European EQ-5D value set. However,Table 3
Effects model of KCCQ at time point 24 weeks with and without baseline HRQoL.
Coef. 95% CI
Predictor Model without baseline HRQoL (n = 425)
i.v. iron 6.67 2.80; 10.54
NYHA class 11.15 5.74; 16.56
eGFR† 0.16 0.07; 0.25
Stroke −7.42 −14.46; −0.37
6-min walk test 0.03 0.01; 0.05
Hypertension – –
KCCQ baseline⁎ – –
Poland Reference
Argentina 4.43 −15.00; 23.86
Czech Republic −6.00 −16.47; 4.48
Germany −17.22 −29.84; 4.60
Spain −10.42 −22.53; 1.69
Greece −23.43 −37.10; −9.75
Italy −18.74 −31.36; −6.12
Norway −5.04 −32.59; 22.51
Romania 5.44 −5.51; 16.39
Russia −17.55 −23.23; −11.88
Ukraine −15.93 −22.48; −9.38
Constant 53.35
All countries combined: p b 0.01.
eGFR, estimated glomerular ﬁltration rate; i.v., intravenous; TSAT, transferrin saturation.
⁎ Per increase by 1.
† For a one unit increase in eGFR (mL/min).given small patient numbers in some countries, the observed differ-
ences may partially be centre-effects in some countries.
The distinct inﬂuence of NYHA class and exercise tolerance (6-min
walk test) on HRQoL observed in our results is in line with ﬁndings in
the literature [10,5,6,23,24]. It has also been reported that kidney
function is an important factor for a patient's HRQoL, a result which
we could reproduce in our model [25]. The observation of a signiﬁcant
impact of history of stroke on HRQoL is also consistent with the liter-
ature [26,27]. History of ischaemic heart disease and hypertension
had an effect on HRQoL in some sensitivity analyses. Such associa-
tions were also previously reported [28,29] and might have been
stronger if the analysis had not been done in a population entirely
affected by CHF. We could not conﬁrm inﬂuences of gender, BMI
or haemoglobin level, in contrast to previous reports based on uni-
variate analysis [16,30–32]. In contrast to ﬁndings in the literaturep Coef. 95% CI p
Model with baseline HRQoL (n = 448)
b0.01 6.60 3.17; 10.03 b0.01
b0.01 – – –
b0.01 0.20 0.12; 0.27 b0.01
0.04 −7.29 −13.56; −1.03 0.02
0.01 – – –
– 4.83 0.49; 9.17 0.03
– 0.56 0.48; 0.65 b0.01
Reference
0.65 −0.41 −17.78; 16.95 0.96
0.26 −11.69 −21.05; −2.34 0.01
b0.01 −20.97 −32.11; −9.84 b0.01
0.09 −20.36 −31.26; −9.45 b0.01
b0.01 −18.21 −29.63; −6.79 b0.01
b0.01 −16.93 −28.00; −5.87 b0.01
0.72 −9.16 −33.40; 15.08 0.46
0.33 0.65 −9.06; 10.37 0.90
b0.01 −18.76 −23.92; −13.60 b0.01
b0.01 −17.42 −23.13; −11.70 b0.01
27.63
3883F.S. Gutzwiller et al. / International Journal of Cardiology 168 (2013) 3878–3883[7], depression, in our analysis represented by the EQ-5D anxiety/
depression item, was not found to be a signiﬁcant predictor of
HRQoL expressed as KCCQ scores. This may have been due to si-
multaneous inclusion of baseline KCCQ as a predictor variable, as
the EQ-5D anxiety/depression item would have been signiﬁcant
without baseline KCCQ. It should also be noted that this isolated
use of an item of the EQ-5D, in the absence of a more suitable indi-
cator of depression, is not a validated approach.
Regarding the mechanisms through which the determinants we
found may inﬂuence HRQoL, the primary pathway is most likely via
direct improvement of physiological parameters, such as provision
of oxygen to the body. It is possible that improvement of these
parameters additionally inﬂuences the patients' social activities and
allows them to be more mobile and autonomous. With this in mind,
monitoring of clinical signs and symptoms, and improving them
where needed, should aim at restoring the social activities and con-
tacts of patients, in order to improve their overall HRQoL.
7.2. Limitations
Our population consisted of CHF patients with iron deﬁciency;
iron deﬁciency has been estimated to have a prevalence of b30% in
anaemic CHF patients [33] and of nearly 50% in unselected popula-
tions of stable CHF patients [9]. In populations different from the
one analysed, with different proportions of iron-deﬁcient patients,
predictors of HRQoL and effect sizes might be different from our ob-
served results. A further limitation of our study is that information
on some possible determinants that might be important for a more
complete understanding of the HRQoL of CHF patients was not available
from the FAIR-HF data set. These determinants could include patients'
social status and social support received as well as psychological
well-being. The organisation of care and, speciﬁcally, participation in
disease management programmes may also play a role. Dyspnoea,
orthopnea, fatigue and peak oxygen uptake are further potential factors
of relevance that were not available to us [5,6].
The effect of i.v. iron substitution was observed during a limited
treatment duration and we do not have any information on how
sustainable this effect may be. Further research on the role of this
treatment option should focus on investigating sustained effects of
i.v. iron after substitution and under maintenance therapy.
8. Conclusions
In this study, i.v. iron substitution using FCM, NYHA class, stroke,
country of residence, exercise tolerance and renal function inﬂuenced
measures of HRQoL in CHF patients with iron deﬁciency. Determinants
of HRQoL with easily measurable clinical correlates, such as kidney
function and iron status, should be followed closely; stroke prevention,
improvement of exercise tolerance and improvement in NYHA func-
tional class should have high priority in clinical practise. Information
on important determinants of HRQoL in CHF patients can help clinicians
to identify those at risk of reduced HRQoL and to target interventions
appropriately.
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